Mvasi (bevacizumab-awwb)

Mvasi™ is a biosimilar to Avastin® (bevacizumab) and like Avastin, it is approved to treat adults with certain types of brain, kidney, cervical, colorectal, and lung cancers. Specifically, in lung cancer, Mvasi is approved to treat non-squamous non-small cell lung cancer (NSCLC) in combination with the chemotherapy drugs carboplatin and paclitaxel for first-line treatment of tumors that cannot be operated on (unresectable), are locally advanced, or recurrent or metastatic (has spread to other parts of the body) disease.1

Ingredients

Mvasi is a biosimilar to bevacizumab. It is a targeted therapy that is classified as a monoclonal antibody.1,2

How does Mvasi work?

Like Avastin, Mvasi is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF). By blocking VEGF, Mvasi inhibits the growth of new blood vessels, which are necessary for the growth of solid tumors.1,3

Possible side effects

In clinical trials, the most common side effects experienced by people receiving Mvasi included nose bleeds (epistaxis), headache, high blood pressure (hypertension), inflammation of the nasal cavity (rhinitis), high levels of protein in the urine (proteinuria), taste alteration, dry skin, rectal bleeding (hemorrhage), excessive tear production (lacrimation disorder), back pain and skin irritation (exfoliative dermatitis).1

Some people taking Mvasi have experienced serious side effects such as:

  • Perforation (holes) in the gastrointestinal tract
  • Surgery and wound healing complications
  • Hemorrhage (severe bleeding), which may include pulmonary (lungs), gastrointestinal, central nervous system, or vaginal bleeding and may be fatal1

Other serious side effects that may occur with Mvasi include holes in or abnormal connection between two organs (perforation or fistula), blood clot formation (arterial and venous thromboembolic events), hypertension, problems in brain function or structure (posterior reversible encephalopathy syndrome), high levels of protein in the urine (proteinuria), infusion-related reactions and loss of function of the ovaries (ovarian failure). Mvasi should be discontinued if certain of these side effects occur or if these side effects become life-threatening.1 This is not an exhaustive list of all potential side effects of Mvasi. Talk to your healthcare provider or pharmacist for further information.

Considerations around pregnancy and surgery

Mvasi should not be used by pregnant women as Mvasi may cause harm to a developing fetus. Women who could become pregnant should use birth control while receiving Mvasi and for 6 months following the final dose (patients should discuss appropriate birth control methods with their doctor). Mvasi may impair fertility.1

It is not known whether Mvasi passes into breast milk, and women should not breastfeed while receiving Mvasi and for 6 months following the final dose.1

Mvasi should not be used for at least 28 days prior to major surgery and for at least 28 days following major surgery, as it can delay the healing of surgical wounds.1 Tell your doctor about all health conditions, medications (prescription and over-the-counter), and health history when discussing Mvasi as a treatment option.

How is Mvasi given?

Mvasi is given as an intravenous (IV) infusion. Patients should talk to their doctor if they have any questions, or if they have questions regarding their Mvasi regimen.1

For more information, read the full prescribing information for Mvasi.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

Written by: Emily Downward | Last reviewed: January 2021.